489 studies on Insulin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 489 dated studies on Insulin. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
A study compared the efficacy and glycemic control effects of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents already using metformin.
Understanding how liraglutide specifically modulates brain reward circuits could refine obesity treatment strategies, moving beyond general appetite suppression to more targeted interventions. For peptide users and cl…
If future research confirms a positive effect, liraglutide could represent a valuable adjunctive therapy for Type 1 Diabetes, potentially improving glycemic control, preserving residual beta-cell function, and reducin…
A clinical study is underway to assess how CagriSema, cagrilintide, and semaglutide impact muscle health in overweight individuals with prediabetes during weight loss.
The outcome of this trial could significantly impact the treatment landscape for Type 2 Diabetes. If flexible-dose oral semaglutide demonstrates superior efficacy or a comparable safety profile to sitagliptin, it coul…
Liraglutide's efficacy for glycemic control was compared against metformin monotherapy and metformin/glimepiride combination in 1091 Type 2 Diabetes patients.
Should this trial demonstrate that Insulin Degludec/Liraglutide (IDegLira) significantly improves Time in Range while simultaneously reducing markers of inflammation and endothelial dysfunction compared to a tradition…
For patients with severe insulin resistance in Type 2 Diabetes, optimizing glycemic control without excessive insulin burden is a critical challenge. High insulin doses often lead to weight gain and hypoglycemia, limi…
If successful, this trial could establish semaglutide as a crucial adjunct therapy for individuals with Double Diabetes, potentially improving glycemic control beyond insulin alone and reducing overall insulin require…
This review provides crucial insights for peptide users and clinicians, clarifying why dual GLP-1R/GIPR agonists like tirzepatide offer superior weight loss and metabolic improvements over single GLP-1RAs like semaglu…
This analysis highlights insulin resistance as a crucial biomarker for predicting liraglutide's efficacy in preventing recurrent stroke and vascular events in type 2 diabetes patients. For clinicians and biohackers, t…
Tirzepatide's real-world efficacy in improving sleep-disordered breathing offers a significant practical takeaway for clinicians and individuals managing obesity and type 2 diabetes. Beyond weight loss and glycemic co…
This case underscores the critical importance for clinicians to maintain a high index of suspicion for euglycemic ketoacidosis in patients using tirzepatide, even with normal blood glucose levels. The severe presentat…
This finding offers a promising new therapeutic avenue for managing Fabry disease, particularly for patients experiencing residual proteinuria despite current standard-of-care treatments. DUAL GIP/GLP-1Ra could signif…
If successful, this combination therapy could offer a refined approach for GHD patients with glucose dysregulation. Current GH replacement protocols, while beneficial for body composition, can sometimes worsen insulin…
This Phase 3 trial represents a crucial step in exploring Liraglutide as an adjunctive therapy for Type 1 Diabetes, a population with significant unmet needs beyond insulin. If the study's hypotheses were confirmed, i…
If successful, this trial could represent a significant paradigm shift in managing Type 1 Diabetes Mellitus, moving beyond mere symptom management to actively preserving endogenous insulin production. For individuals …
Liraglutide's use as an add-on treatment for **Type 1 Diabetes Mellitus** patients was retrospectively evaluated in a chart review.
This head-to-head Phase 3 trial is crucial for understanding the comparative efficacy and safety of Tirzepatide versus Semaglutide in Type 2 Diabetes patients already on metformin. The results will directly inform cli…
This registry holds significant implications for understanding the pleiotropic effects of tirzepatide beyond its established metabolic benefits. For peptide users and clinicians, the data could illuminate whether tirz…
Liraglutide's ability to improve insulin secretion, reduce exogenous insulin requirements, and its safety in early-diagnosed Type 1 Diabetes patients (10-30 years) was investigated in a Phase 2 trial.
If successful, cagrilintide could represent a valuable addition to the therapeutic landscape for overweight and obesity, offering a novel mechanism of action through amylin agonism. This Phase 1 trial is critical for …
This trial represents a crucial step in exploring preventative strategies for Type 1 Diabetes, moving beyond reactive management. If liraglutide proves effective in preserving beta cell function and delaying disease o…
This Phase 1 trial represents a significant step towards identifying novel adjunctive therapies for Type 1 Diabetes, moving beyond insulin-only regimens. If NNC0194-0499 proves safe and demonstrates promising prelimin…
If positive, this research could significantly impact Type 1 Diabetes management, offering a novel adjunctive strategy to improve glycemic control and potentially mitigate common issues like weight gain or post-meal s…
If positive, this trial could represent a significant advancement in the treatment of obstructive sleep apnea, particularly for individuals with co-morbid obesity. Tirzepatide could offer a pharmacological alternative…
This foundational dataset provides an unprecedented tool for understanding diabetic microvascular disease at a systemic level, moving beyond organ-specific views. For researchers and clinicians, it offers a quantitati…
If the hypothesis is confirmed, this research could establish a novel, more effective treatment paradigm for type 2 diabetes and obesity specifically tailored for postmenopausal women. The synergistic effects of addre…
If successful, this trial could establish Semaglutide as a crucial adjunctive therapy for men with prostate cancer on ADT, significantly improving their quality of life and long-term health outcomes. The practical tak…
This optimized mini-tag strategy offers a significant advancement for the scalable and economical production of GLP-1 analogs and other therapeutic peptides. By focusing on mass fraction optimization, which minimizes …
Understanding the local pharmacokinetics of IGF-I in muscle tissue is critical for optimizing therapeutic strategies for Type 1 Diabetes Mellitus. If the microdialysis technique proves reliable for measuring interstit…
The continuation of similar monitoring efforts, as seen in the ongoing Increlex® Global Registry (NCT00903110), underscores the importance of continuous post-market surveillance for this patient population.
This large-scale observational study is critical for understanding the true health impact of androgenic anabolic steroid (AAS) use among recreational athletes, a population with alarmingly high prevalence. The finding…
A sublingual liraglutide formulation could revolutionize T2DM management by offering a highly convenient, non-injectable alternative to current GLP-1R agonists. This would significantly enhance patient adherence and q…
The development of an oral formulation for a highly effective GLP-1 analogue like semaglutide represents a significant step forward for Type 2 Diabetes management. Oral semaglutide offers enhanced patient convenience …
This large-scale observational study is crucial for understanding the real-world comparative effectiveness of tirzepatide against other leading GLP-1RAs in preventing Major Cardiovascular Events in patients with Type …
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in …
GLP-1 Receptor Agonists' effects on BMI, HOMA-IR, and total testosterone in Polycystic Ovary Syndrome were assessed by a meta-analysis, but no quantitative results are reported in the abstract.
The investigation into recombinant human insulin-like growth factor I (IGF-I) as a treatment for hyperinsulinism is significant due to the limitations of existing therapies. If IGF-I effectively reduces insulin secret…
This study provides promising early evidence that recombinant human growth hormone (rhGH) could be a safe and effective therapeutic option for adolescents grappling with NAFLD. The observed improvements in liver fat, …
This study provides compelling evidence that an intensive, short-term metabolic intervention can lead to sustained remission of Type 2 Diabetes, moving beyond mere disease management. The combination of IDegLira, metf…
First-in-human Phase 2 trial of GSK2890457 investigated its safety, tolerability, and pharmacodynamics in healthy volunteers and Type 2 Diabetes subjects.
Lixisenatide and Liraglutide's pharmacodynamic effects on post-prandial glucose and C-peptide were compared in 142 T2DM patients on insulin glargine.
This study design highlights a critical need to understand how different incretin-based therapies impact Type 2 Diabetes management, especially in diverse populations. While the specific results are not detailed, the …
A randomized controlled trial investigated Liraglutide's effects on chylomicron/VLDL kinetics, liver fat, and de novo lipogenesis in type 2 diabetes.
This Phase 3 trial is pivotal for the future of Type 2 Diabetes management, potentially introducing a new, highly effective oral GLP-1R agonist. If Orforglipron demonstrates comparable or superior efficacy and a favor…
This study is critically important for enhancing patient safety during surgical procedures for individuals using GLP-1 RAs. The findings will directly inform updated preoperative fasting guidelines, potentially preven…
Obesity-related HFpEF is a major public health challenge with few targeted treatments, making the potential of Tirzepatide highly significant. If this study successfully identifies the mechanisms by which Tirzepatide …
This trial is crucial because it seeks to provide a much-needed treatment option for obesity in individuals with Type 1 Diabetes, a population with limited pharmacological interventions. A successful outcome could sig…
Free, no account — handy when you're working with Insulin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account